Leiv Ose
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leiv Ose has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Kjetil Retterstøl
Department of Nutrition, Institute of Basic Medical Sciences University of Oslo Oslo Norway
3 shared publications - Kirsten Bjørklund Holven
Norwegian National Advisory Unit on Familial Hypercholesterolemia, Oslo University Hospital, Oslo, Norway
2 shared publications - Bente Halvorsen
Oslo University Hospital Rikshospitalet, Research Institute of Internal Medicine, Oslo, Norway; University of Oslo, Institute of Clinical Medicine, Oslo, Norway; University of Oslo, K.G. Jebsen Inflammatory Research Center, Oslo, Norway
1 shared publication - Bente Halvorsen
Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway
1 shared publication Ingebjørg Seljeflot
Center for Clinical Research, Ullevaal University Hospital, Oslo, Norway
1 shared publication- Ingunn Narverud
Oslo University Hospital Ulleval, Norwegian National Advisory Unit on Familial Hypercholesterolemia , Oslo , Norway
1 shared publication
Latest Publications
- 1 August 2014
- Published by Elsevier in Atherosclerosis
- Vol. 235 (2) , 299-309
Markers of atherosclerotic development in children with familial hypercholesterolemia: A literature review
- 1 August 2014
- Published by Elsevier in Atherosclerosis
- Vol. 235 (2) , 299-309
Markers of atherosclerotic development in children with familial hypercholesterolemia: A literature review
- 31 December 2007
- Published by Elsevier in Thrombosis Research
- Vol. 120 (1) , 21-27
Altered hemostatic balance and endothelial activation in pregnant women with familial hypercholesterolemia
- 31 December 2007
- Published by Elsevier in Thrombosis Research
- Vol. 120 (1) , 21-27
Altered hemostatic balance and endothelial activation in pregnant women with familial hypercholesterolemia
- 1 July 2006
- Published by Wolters Kluwer Health in Stroke
- Vol. 37 (7) , 1731-1736
Impaired Inhibitory Effect of Interleukin-10 on the Balance Between Matrix Metalloproteinase-9 and Its Inhibitor in Mononuclear Cells From Hyperhomocysteinemic Subjects
Background and Purpose—Homocysteine has been linked to increased risk of ischemic stroke and other cardiovascular events, but the mechanism by which elevated plasma levels of homocysteine promotes atherogenesis remains unclear. Matrix degradation, partly regulated by the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs), plays an important role in atherogenesis and plaque destabilization, and we hypothesized an imbalance between MMPs and TIMPs in hyperhomocysteinemia.Methods—Serum MMP-9 and TIMP-1 was measured in 12 hyperhomocysteinemic and 12 control subjects. The release of MMP-9 and TIMP-1, with and without interleukin-10 (IL-10), and the effect of IL-10 on signal transducer and activator of transcription 3 (STAT3) phosphorylation were measured in peripheral blood mononuclear cells (PBMCs) from hyperhomocysteinemic and control subjects.Results—Our main findings were: (1) hyperhomocysteinemic subjects had raised serum levels of MMP-9 and MMP-9/TIMP-1 ratio comparing healthy controls; (2) although IL-10 markedly suppressed MMP-9 release from PBMCs in controls, no or only minor effect was seen in hyperhomocysteinemic subjects; (3) although IL-10 enhanced TIMP-1 levels in PBMCs from both hyperhomocysteinemic and control subjects, the increase was more prominent in controls, resulting in a marked difference in IL-10–induced changes in MMP-9/TIMP-1 ratio between these 2 groups; and (4) comparing PBMCs from controls, cells from hyperhomocysteinemic individuals had impaired IL-10–induced STAT3 phosphorylation.Conclusions—Our findings suggest an attenuated inhibitory response to IL-10 on MMP-9 activity in hyperhomocysteinemic subjects, potentially promoting atherogenesis and plaque instability, representing a novel explanation for increased risk for atherosclerotic disease in these individuals.
- 1 July 2006
- Published by Wolters Kluwer Health in Stroke
- Vol. 37 (7) , 1731-1736
Impaired Inhibitory Effect of Interleukin-10 on the Balance Between Matrix Metalloproteinase-9 and Its Inhibitor in Mononuclear Cells From Hyperhomocysteinemic Subjects
Background and Purpose—Homocysteine has been linked to increased risk of ischemic stroke and other cardiovascular events, but the mechanism by which elevated plasma levels of homocysteine promotes atherogenesis remains unclear. Matrix degradation, partly regulated by the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs), plays an important role in atherogenesis and plaque destabilization, and we hypothesized an imbalance between MMPs and TIMPs in hyperhomocysteinemia.Methods—Serum MMP-9 and TIMP-1 was measured in 12 hyperhomocysteinemic and 12 control subjects. The release of MMP-9 and TIMP-1, with and without interleukin-10 (IL-10), and the effect of IL-10 on signal transducer and activator of transcription 3 (STAT3) phosphorylation were measured in peripheral blood mononuclear cells (PBMCs) from hyperhomocysteinemic and control subjects.Results—Our main findings were: (1) hyperhomocysteinemic subjects had raised serum levels of MMP-9 and MMP-9/TIMP-1 ratio comparing healthy controls; (2) although IL-10 markedly suppressed MMP-9 release from PBMCs in controls, no or only minor effect was seen in hyperhomocysteinemic subjects; (3) although IL-10 enhanced TIMP-1 levels in PBMCs from both hyperhomocysteinemic and control subjects, the increase was more prominent in controls, resulting in a marked difference in IL-10–induced changes in MMP-9/TIMP-1 ratio between these 2 groups; and (4) comparing PBMCs from controls, cells from hyperhomocysteinemic individuals had impaired IL-10–induced STAT3 phosphorylation.Conclusions—Our findings suggest an attenuated inhibitory response to IL-10 on MMP-9 activity in hyperhomocysteinemic subjects, potentially promoting atherogenesis and plaque instability, representing a novel explanation for increased risk for atherosclerotic disease in these individuals.